PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020
Visit https://www.peervoice.com/QTK860 to view the entire programme with slides. After completing “SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.